The Technical Analyst
Verrica Pharmaceuticals [VRCA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Verrica Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.86% $7.06
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 299.48 mill |
| EPS: | -1.480 |
| P/E: | -4.77 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 42.42 mill |
| Avg Daily Volume: | 0.138 mill |
| RATING 2024-04-17 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.77 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.81x |
| Company: PE -4.77 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.420 (-94.05%) $-6.64 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.70 - 7.40 ( +/- 4.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-15 | Hayes Christopher G. | Buy | 40 000 | Common Stock |
| 2024-03-15 | Hayes Christopher G. | Buy | 80 000 | Employee Stock Option (right to buy) |
| 2024-03-15 | Goldenberg Gary | Buy | 40 000 | Common Stock |
| 2024-03-15 | Goldenberg Gary | Buy | 80 000 | Employee Stock Option (right to buy) |
| 2024-03-15 | Kohler Terry | Buy | 80 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 91.16 |
| Last 98 transactions |
| Buy: 14 420 498 | Sell: 288 608 |
Forecast:
16:00 - $7.06
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $7.06
Forecast 2: 16:00 - $7.06
Forecast 3: 16:00 - $7.06
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.06 (0.86% ) |
| Volume | 0.105 mill |
| Avg. Vol. | 0.138 mill |
| % of Avg. Vol | 75.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VRCA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.20 | N/A | Active |
|---|
VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Last 10 Buy Signals
Latest Press Releases
2024-04-02 07:30:00 - Press Release
Verrica Pharmaceuticals Announces Presentation At The 23rd Annual Needham Virtual Healthcare Conference
West chester, pa., april 02, 2024 (globe newswire) -- verrica pharmaceuticals inc. (“verrica”) (nasdaq: vrca), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that ted white, verrica's president & chief executive officer, will present at the upcoming 23rd annual needham virtual healthcare conference, which is being held virtually from april 8-11, 2024.
2024-03-26 07:30:00 - Press Release
Verrica Pharmaceuticals Announces That Ycanth™ Receives New Chemical Entity Status And Orange Book Listing From The Fda
Nce status provides a minimum of five years of regulatory exclusivity the company's u.s. patents and pending patent applications related to ycanth™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension west chester, pa., march 26, 2024 (globe newswire) -- verrica pharmaceuticals inc. (“verrica” or “the company”) (nasdaq: vrca), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the company's lead product, ycanth™, has received new chemical entity (“nce”) status and a listing in the orange book from the u.s. food and drug administration (“fda”), providing a minimum five years of regulatory exclusivity.
2024-02-29 07:30:00 - Press Release
Verrica Pharmaceuticals Reports Fourth Quarter And Full-year 2023 Financial Results
– reports ycanth™ revenue of $1.9m for fourth quarter and $4.7m for full year 2023 – – over 200 million lives now covered on commercial insurance and managed medicaid plans – – conference call scheduled for today at 8:30 am et – west chester, pa., feb. 29, 2024 (globe newswire) -- verrica pharmaceuticals inc. (“verrica”) (nasdaq: vrca), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended december 31, 2023.
2024-02-27 07:30:00 - Press Release
Verrica Pharmaceuticals Announces Participation In The Td Cowen 44th Annual Healthcare Conference
West chester, pa., feb. 27, 2024 (globe newswire) -- verrica pharmaceuticals inc. (“verrica” or “the company”) (nasdaq: vrca), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the td cowen 44th annual healthcare conference, which will be held in boston, massachusetts.
2024-02-22 07:30:00 - Press Release
Verrica Pharmaceuticals To Provide A Corporate Update And Report Fourth Quarter And Full-year 2023 Financial Results On February 29, 2024
West chester, pa., feb. 22, 2024 (globe newswire) -- verrica pharmaceuticals inc. (“verrica” or “the company”) (nasdaq: vrca), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. et on thursday, february 29, 2024 to provide a corporate update and discuss the company's financial results for the fourth quarter and full-year ended december 31, 2023.
Latest News
2024-02-29 12:22:04 - Seeking Alpha
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
2024-02-22 07:30:00 - GlobeNewsWire
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company's financial results for the fourth quarter and full-year ended December 31, 2023.
2024-01-22 19:44:13 - InvestorPlace
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
You want potential short-squeeze stocks that could have the bears running for cover? Great, we got ‘em right here!
2023-12-31 10:10:40 - 24/7 Wall Street
Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, biotechs were in focus among the notable insider purchases.
2023-12-23 09:03:06 - 24/7 Wall Street
Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.
2023-12-15 13:49:30 - InvestorPlace
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
Shares of Verrica Pharmaceuticals (NASDAQ: VRCA ) skyrocketed on Friday thanks to positive late-stage clinical trial results. Specifically, Verrica — along with its development and commercialization partner Torii Pharmaceutical — reported positive top-line results from its Phase 3 trial of TO-208 for the treatment of molluscum contagiosum in Japan.
2023-10-25 07:00:00 - GlobeNewsWire
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 9, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023.
2023-08-31 08:00:00 - GlobeNewsWire
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted White, Verrica President and CEO, will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 5:00 pm ET. The Company will also be participating in one-on-one meetings during the conference.
2023-07-24 15:16:36 - The Motley Fool
Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday
Verrica focuses on dermatology therapeutics. The company just received approval for its first marketed product.
2023-07-24 07:00:00 - GlobeNewsWire
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET
WEST CHESTER, Pa., July 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company has entered into a non-binding term sheet for a term loan facility of up to $125 million, which the Company expects to close by the end of this week.